Navigation Links
Callisto Reports on Second-Quarter 2007 Milestones
Date:8/19/2007

hetic molecule) of uroguanylin developed by Callisto scientists, and is proprietary to Callisto. Guanilib has been demonstrated to be superior to uroguanylin in its biological activity, protease stability and pH characteristics, and is currently undergoing pre-clinical animal studies as a treatment for gastrointestinal (GI) diseases and GI inflammation. Animal model data on Guanilib previously demonstrated anti-inflammatory activity in a number of mouse-models of ulcerative colitis, and the drug is currently being evaluated in animal models of GI disorders. Callisto plans to initiate clinical trials of Guanilib in early 2008.

About Atiprimod

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and gastrointestinal diseases. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including gastrointestinal disorders. One of the Company's lead drug candidates, Atiprimod is presently in a Phase II clinical trial in advanced carcinoid cancer patients, a neuroendocrine tumor, and in a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory ac
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 29, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, is committed to pursuing ... developed an innovative, patent-pending dual carrier transdermal delivery ... pharmaceutical active ingredients to penetrate the skin and ... The transdermal delivery method also overcomes microbial drug ...
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli ... details of its long-standing technology transfer program to increase ... Begun in 2003, the effort included Lilly donating manufacturing ... in China , India ... South Africa – all MDR-TB ,hot ...
(Date:10/27/2014)... CHICAGO , Oct. 27, 2014  Demonstrations ... and devices are being featured this week in ... 2014 Scientific Assembly where more than 7,000 emergency ... medicine and participating in educational courses. ... back drop of true-to-life emergency department environments, including ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
(Date:10/28/2014)... "Epithelial cell layers line all of the inner and ... for example in the lung, intestine, pancreas and in ... hair-like, microtubule-based structures – project from BBs and are ... through this exact positioning can cilia movements be coordinated ... from the lung or sound can be perceived from ...
(Date:10/28/2014)... hormonal therapy is known to substantially reduce breast ... about one-half of patients fail to take their ... Medical Center (CUMC) researchers has found that the ... type of hormone therapy), which are considerably less ... by 50 percent. , The study was published ...
(Date:10/28/2014)... study, researchers from Uppsala University demonstrate that elderly ... risk of developing Alzheimer,s disease than men without ... the scientific journal Alzheimer,s & Dementia . ... who were initially 50 year old, between the ... study show that self-reported sleep disturbances were linked ...
(Date:10/27/2014)... price tag for informal caregiving of elderly people by ... $522 billion a year, according to a new RAND ... care at minimum wage would cost $221 billion, while ... $642 billion annually. , The study, published online ... estimates about the value of informal caregiving by making ...
(Date:10/27/2014)... Do blood vessels that feed tumors differ from other blood ... led to the discovery of several genes that are more ... New research now reveals the normal function of one of ... for anticancer drug therapy. , A summary of the research ... 27. , The mystery of the gene, TEM5, began in ...
Breaking Medicine News(10 mins):Health News:New insights into the development of ciliopathies 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:Blood vessel growth in the brain relies on a protein found in tumor blood vessels 2
... life hangs between life and death, suffering an extremely rare ... transplant, which will give him a new lease of life. ... will be donating a kidney each. , ,Mrs ... felt so helpless, especially as you're used to doing everything ...
... confirmed that the bird flu virus found in poultry in ... to humans as well //. ,As chief veterinarian ... laboratory that it was the highly pathogenic H5N1 strain of ... ,This is the first report of the H5N1 virus in ...
... Hospital's two pediatricians, Jo McCubbin and Peter Goss have ... months notice //. However a full time replacement ... ,This has led to concerns among obstetricians at ... obstetricians would not be able to deliver premature babies ...
... of laws was initiated by Quebec Health Minister Philippe Couillard ... health-care insurance //. ,The Supreme Court of Canada ... on June 9, 2005,ruling that Quebec had failed to prove ... medicare, was justified. However with the development of Bill ...
... Ramadoss Friday warned of "strong action" against "indiscipline" he ... of Medical Sciences// (AIIMS), saying a coterie had turned ... people have converted the AIIMS into a political hub ... return to New Delhi June 19," Ramadoss told reporters ...
... the Karolinska Institutet they have found ways to control the ... intestinal stem cell. The result of the study was published ... help in the development of new drugs for diseases such ... body, old cells are continually being replaced by new. If ...
Cached Medicine News:Health News:Quebecers To Choose Private Health-Care Insurance 2Health News:Mechanism of Stem Cell Regulation Identified 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... II Hybrid External Fixation System incorporating ... in hybrid fixation. It incorporates features ... is designed to offer speed of ... Hoffmann® snap-fit technology. , ,Using the ...
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
Medicine Products: